fda bpc 157 unapproved peptide warning bpc-157 drug letter Targets GLP-1 and Compounding, Advertising and 'Research Use Only' Labeling FDA Issues Warning Letters Against – FDA panel narrowly backs unapproved

not approved

Innovative chemical synthesis and conformational hints on the lipopeptide liraglutide

It arrives as a lyophilized powder and needs to be reconstituted before use

Final action: After consideration of public comments, we are finalizing, as proposed, the requirement that, beginning January 1, 2026, hospitals must report, in a newly created general data element in the MRF, any Type 2 NPI(s) that are associated with a primary taxonomy code starting with `28' (indicating hospital) or `27' (indicating hospital unit) and that is active as of the date of the most recent update to the standard charge information